ArticleBreast cancer (Tokyo, Japan)2026
Low-progesterone receptor expression predicts nodal pathological complete response after neoadjuvant chemotherapy in premenopausal patients with ER-positive/HER2-negative breast cancer.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEstrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) shows heterogeneous response to neoadjuvant chemotherapy (NAC). Although low progesterone receptor (PgR) has been associated with greater chemosensitivity, it is unclear whether its predictive value differs according to menopausal status.
methodsWe retrospectively analyzed 213 patients with node-positive, ER-positive/HER2-negative BC who underwent surgery and axillary lymph node dissection (ALND) after NAC between January 2010 and April 2025. All patients received anthracycline- and taxane-based regimens. Multivariable logistic regression was performed to identify predictors of achieving pathological complete response in the axillary lymph node (ypN0), and interaction terms were included to evaluate whether the effect of PgR differed according to menopausal status.
resultsAmong 213 patients, 47 (22%) achieved ypN0. Clinical complete response (OR 5.29; 95% CI 1.44–19.40; p = 0.01) and high Ki-67 (≥ 30%) (OR 3.62; 95% CI 1.14–11.50; p = 0.03) independently predicted ypN0. Low PgR expression (≤ 5%) and premenopausal status were not independently associated with ypN0. In the final multivariable interaction model, the interaction between low PgR (≤ 5%) and premenopausal status remained significant (OR 9.52; 95% CI 1.22–74.50; p = 0.03).
conclusionsThe association between low PgR status (≤ 5% vs. > 5%) and ypN0 after NAC may differ according to menopausal status and appeared to be more pronounced in premenopausal patients with ER-positive/HER2-negative BC. PgR assessment may help identify patients more likely to achieve ypN0 and may provide additional information for future studies evaluating axillary de-escalation.
Indexed as
Identifiers
41944956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.